Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000234702 | SCV000289002 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-11-08 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 8 of the RAD50 gene. It does not directly change the encoded amino acid sequence of the RAD50 protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs776276760, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with RAD50-related conditions. ClinVar contains an entry for this variant (Variation ID: 240209). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). RNA analysis performed to evaluate the impact of this variant on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV000234702 | SCV000663746 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-05-08 | criteria provided, single submitter | clinical testing | The c.1245+2C>G intronic variant results from a C to G substitution two nucleotides after coding exon 8 in the RAD50 gene. This nucleotide position is conserved through primates but not in all available vertebrate species. The BDGP and ESEfinder splice site prediction tools do not produce a reliable prediction for the nearby native splice donor site. The HSF splice site prediction tool does not predict any significant impact on the native splice donor site. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |